WHO grants emergency approval to 2nd Chinese COVID vaccine

Business

FILE – In this Friday, May 28, 2021 file photo, a healthcare worker prepares a dose of the Sinovac COVID-19 vaccine during a vaccination session for medical staff who work at private clinics in Caracas, Venezuela. The World Health Organization has issued an emergence use listing for the COVID-19 vaccine made by Sinovac in adults aged 18 and over, the second such authorization it has granted to a Chinese company. In a statement on Tuesday, June 1 the U.N. health agency said data submitted to its experts showed that two doses of the vaccine prevented people from getting symptoms of COVID-19 in about half of those who got the vaccine.(AP Photo/Matias Delacroix, file)

GENEVA (AP) — The World Health Organization has issued an emergency use listing for the COVID-19 vaccine made by Sinovac for adults 18 and over, the second such authorization it has granted to a Chinese company.

In a statement Tuesday, the U.N. health agency said data submitted to its experts showed that two doses of the vaccine prevented people from getting symptoms of COVID-19 in about half of those who got the vaccine. WHO said there were few older adults enrolled in the research, so it could not estimate how effective the vaccine was in people over 60.

“Nevertheless, WHO is not recommending an upper age limit for the vaccine,” the agency said, adding that data collected from Sinovac’s use in other countries “suggest the vaccine is likely to have a protective effect in older persons.”

In April, a study published by a team of scientists in Brazil confirmed a previously reported efficacy rate of over 50% for Sinovac. A real-world study in Chile in April found an efficacy rate of 67%.

Last month, WHO gave the green light to the COVID-19 vaccine made by Sinopharm. It has also licensed vaccines developed by Pfizer-BioNTech, AstraZeneca, Moderna and Johnson & Johnson.

WHO’s authorization means the vaccine can be bought by donors and other U.N. agencies for use in poorer countries, including in the U.N.-backed initiative to distribute COVID-19 vaccines globally known as COVAX. The effort has been slowed considerably after its biggest supplier in India said it would not be able to provide any more vaccines until the end of the year due to the latest surge of new infections now ravaging India.

To date, there is no confirmed deal for Sinovac doses with COVAX.

In May, Europe’s drug regulator began an expedited review process for the Sinovac vaccine, but it’s unclear when a decision might be made about its possible authorization for the 27-nation bloc.

Hundreds of millions of Chinese vaccineshave already been delivered to dozens of countries around the world through bilateral deals, as many nations scrambled to secure supplies after rich countries reserved the vast majority of supplies from Western pharmaceutical makers.

While China has five vaccine shots in use, the majority of its exports abroad come from two companies: Sinopharm and Sinovac. The Chinese vaccines are “inactivated” vaccines, made with killed coronavirus.

Most other COVID-19 vaccines being used around the world, particularly in the West, are made with newer technologies that instead target the “spike” protein that coats the surface of the coronavirus.

___

Follow AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic and https://apnews.com/hub/coronavirus-vaccine

Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

TRENDING STORIES